Tuesday, January 16, 2018 -- NewsRoche’s Ocrevus (ocrelizumab) approved in the European Union for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis.Contributed Author: Roche Holding AG
Monday, January 15, 2018 -- PET imaging may improve diagnosis and monitoring for MS patients...
Saturday, January 13, 2018 -- MedicalResearch.com Interview with: Fredrik Piehl MD PhD, prof. of Neurology Neuroimmunology Unit. Dept Clinical Neuroscience Neurology Dept. Karolinska University Hospital (Solna) Stockholm MedicalResearch.com: What is the background for this study? What are the main findings? Response: In recent years we have … Continue reading →
Thursday, January 11, 2018 -- BACKGROUND AND PURPOSE: Arterial and neck vessel system characteristics of patients with multiple sclerosis have not been previously investigated. Therefore, the aim of this study was to examine the frequency of neck vessels and their cross-sectional areas (in square millimeters) between patients with MS and healthy controls. MATERIALS AND METHODS: In this study, 193 patients with MS and 193 age- and sex-matched healthy controls underwent 2D TOF venography at 3T. The main arterial (carotid and vertebral), venous (internal jugular), and secondary neck vessels were examined at 4 separate cervical levels (C2/3, C4, C5/6, and C7/T1). The ANCOVA adjusted for age, body mass index, smoking status, hypertension, and heart disease was used to compare the differences between patients with MS
Thursday, January 11, 2018 -- BACKGROUND AND PURPOSE: The spatial correlation between WM and cortical GM disease in multiple sclerosis is controversial and has not been previously assessed with perfusion MR imaging. We sought to determine the nature of association between lobar WM, cortical GM, volume and perfusion. MATERIALS AND METHODS: Nineteen individuals with secondary-progressive multiple sclerosis, 19 with relapsing-remitting multiple sclerosis, and 19 age-matched healthy controls were recruited. Quantitative MR perfusion imaging was used to derive CBF, CBV, and MTT within cortical GM, WM, and T2-hyperintense lesions. A 2-step multivariate linear regression (corrected for age, disease duration, and Expanded Disability Status Scale) was used to assess correlations between perfusion and volume measures in global and lobar normal-appearing WM, cortical GM, and T2-hyperintense lesions.
Wednesday, January 10, 2018 -- SOUTH SAN FRANCISCO, Calif., Jan. 10, 2018 -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral...
Tuesday, January 09, 2018 -- FINDINGS A study by UCLA researchers reveals the cellular basis for how the hormone estrogen protects against damage to the central nervous system in women with multiple sclerosis, or MS. The researchers found that estrogen treatment exerts positive effects on two types of cells during disease — immune cells in the brain as well as cells called oligodendrocytes. BACKGROUND UCLA Dr. Rhonda Voskuhl Multiple sclerosis is a chronic autoimmune, neurodegenerative disease marked by visual impairment, weakness and sensory loss, as well as cognitive decline. These symptoms emerge when inflammatory immune cells destroy the myelin sheath that surrounds nerve cells, known as axons, and that acts as a form of protective insulation for those cells. The third trimester of pregnancy
Monday, January 08, 2018 -- FINDINGS A UCLA study found that gene expression in specific cells and in specific regions of the body can provide a more precise, neuroprotective approach than traditional treatments for neurological diseases. Gene expression is the process by which genetic instructions are used to synthesize gene products, such as proteins, which go on to perform essential functions. For multiple sclerosis, specifically, increasing cholesterol synthesis gene expression in astrocytes of the spinal cord can be a pathway to repair nerves that affect walking. BACKGROUND Multiple sclerosis is an autoimmune, neurodegenerative disease characterized by distinct disabilities that affect walking, vision and cognition. The disease causes inflammation, which strips the myelin coating from nerves. The myelin loss disrupts signaling and eventually causes permanent
Friday, January 05, 2018 -- By: Dr. John Conde, DC, DACNB Special to the Boca and Delray newspapers Over the last 10-15 years, there has been an explosion in neuroscience based research and its non-pharmaceutical clinical applications to brain dysfunction. Simply put, understanding how the brain works so that when something goes wrong we can identify the pathways in the […]
Thursday, January 04, 2018 -- Paris, January 4 2018, 5.45pm AB Science announces that based on interim analysis, IDMC recommended the continuation of the masitinib phase 3 study in progressive forms of multiple sclerosis with no requirement to...
Thursday, January 04, 2018 -- MedicalResearch.com Interview with: Netta Levin MD PhD fMRI lab Neurology Department Hadassah Hebrew University Medical Center Jerusalem MedicalResearch.com: What is the background for this study? Response: Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system, manifesting … Continue reading →
Wednesday, January 03, 2018 -- Pain is a common and severe symptom in multiple sclerosis (MS), a chronic inflammatory and demyelinating disease of the CNS. The neurobiological mechanism underlying MS pain is poorly understood. In this study, we investigated the role of Ca2+/calmodulin-dependent protein kinase IIα (CaMKIIα) in driving chronic pain in MS using a mouse experimental autoimmune encephalomyelitis (EAE) model. We found that spinal CaMKIIα activity was enhanced in EAE, correlating with the development of ongoing spontaneous pain and evoked hypersensitivity to mechanical and thermal stimuli. Prophylactic or acute administration of KN93, a CaMKIIα inhibitor, significantly reduced the clinical scores of EAE and attenuated mechanical allodynia and thermal hyperalgesia in EAE. siRNA targeting CaMKIIα reversed established mechanical and thermal hypersensitivity in EAE mice.
Wednesday, January 03, 2018 -- While both intravenous and oral administrations of methylprednisolone showed similar efficacy, the investigators noted that oral administration may be more tolerable and cost-effective.
Thursday, December 21, 2017 -- The 2016 MAGNIMS criteria showed similar accuracy to the 2010 McDonald criteria in predicting the development of clinically definite multiple sclerosis. Inclusion of symptomatic lesions is expected to simplify the clinical use of MRI criteria without reducing accuracy, and our findings suggest that needing three lesions to define periventricular involvement might slightly increase specificity, suggesting that these two factors could be considered during further revisions of multiple sclerosis diagnostic criteria.
Wednesday, December 20, 2017 -- The antidepressant clomipramine may also alleviate symptoms of multiple sclerosis (MS), specifically in its progressive form, i.e. when it occurs without relapses or remissions.
Wednesday, December 20, 2017 -- The FDA has granted Breakthrough Therapy designation to Fingolimod for treating children with relapsing multiple sclerosis.
Thursday, December 14, 2017 -- A METHOD for quickly detecting signs of multiple sclerosis has been developed by a University of Huddersfield research team.
Friday, December 08, 2017 -- Those who ate the healthiest diet consumed an average of 1.7 servings of whole grains per day.
Thursday, December 07, 2017 -- Gut bacteria dysbiosis during young adulthood may be involved in the development of multiple sclerosis (MS), according to a recent study in Proceedings of the National Academy of Sciences.
Wednesday, December 06, 2017 -- Investigations into brain function and disease depend on the precise classification of neural cell types. Cells of the oligodendrocyte lineage differ greatly in their morphology, but accurate identification has thus far only been possible for oligodendrocyte progenitor cells and mature oligodendrocytes in humans. We find that breast carcinoma amplified sequence 1 (BCAS1) expression identifies an oligodendroglial subpopulation in the mouse and human brain. These cells are newly formed, myelinating oligodendrocytes that segregate from oligodendrocyte progenitor cells and mature oligodendrocytes and mark regions of active myelin formation in development and in the adult. We find that BCAS1+ oligodendrocytes are restricted to the fetal and early postnatal human white matter but remain in the cortical gray matter until old age. BCAS1+